Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nano-platform for computer tomography theranostics.
Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nano-platform for computer tomography theranostics.
复制标题
DOI：
10.1166/jbn.2014.1725
复制
发表时间：
2014-03
影响因子：
2.9
通讯作者：
N. Chanda;Anandhi Upendran;E. Boote;Ajit P. Zambre;S. Axiak;K. Selting;K. Katti;W. Leevy;Z. Afrasiabi;Jatin Vimal;Jason Singh;J. Lattimer;R. Kannan
中科院分区：
文献类型：
--
作者：
N. Chanda;Anandhi Upendran;E. Boote;Ajit P. Zambre;S. Axiak;K. Selting;K. Katti;W. Leevy;Z. Afrasiabi;Jatin Vimal;Jason Singh;J. Lattimer;R. Kannan
我们研究的目的是证明纳米晶金作为活体肿瘤成像的X射线造影剂的实用性。尽管研究人员在这一领域取得了重大进展，但临床翻译仍然具有挑战性。在这里，我们研究了生物相容阿拉伯胶稳定的金纳米晶(GA-AuNPs)作为X射线造影剂在荷瘤小鼠和狗身上的应用。单次瘤内注射GA-AuNP后1小时，瘤体内X线对比度改变为-26HU。随后，对小鼠进行了五次肿瘤内注射。肿瘤区域CT数的变化不是进行性的，而是在第四次注射后达到饱和点。这些数据表明，GA-AuNP的积聚在短时间内(5h)达到阈值，并在研究期间的其余时间保留在肿瘤组织中。在客户拥有的一只患有甲状腺癌和骨肉瘤碰撞瘤的狗身上进行了一项初步研究。在本研究中，将GA-AuNP注射到犬的肿瘤内，观察到12deltaHU的对比度增强。小鼠和狗的CT图像清楚地表明，GA-AuNP有效地分布并保留在整个肿瘤部位。通过本研究获得的CT数据将为使用该结构的战略治疗计划提供关键的剂量学信息。小鼠和狗均未表现出任何临床变化，从而证实了GA-AuNP没有毒性，可以探索未来的临床应用。
The goal of our study was to demonstrate the utility of nanocrystalline gold as an X-ray contrast agent for imaging tumor in living subjects. Even though significant progress has been achieved in this area by researchers, clinical translation remains challenging. Here, we investigated biocompatible gum Arabic stabilized gold nanocrystals (GA-AuNPs) as X-ray contrast agent in tumor bearing mice and dog. Single intratumoral injections of GA-AuNP resulted in X-ray contrast change of -26 HU in the tumor region after 1 hour post-injection period. Subsequently, five intratumoral injections were performed in the mice. The change in CT number in tumor region is not progressive; rather it reaches a saturation point after fourth injection. These data suggested that accumulation of GA-AuNP reaches a threshold limit within a short time period (5 h), and is retained in the tumor tissue for the rest of the period of investigation. A pilot study was conducted in a client-owned dog presented with collision tumor of thyroid carcinoma and osteosarcoma. In this study, GA-AuNP was injected intratumorally in dog and a contrast enhancement of 12 deltaHU was observed. The CT images of both mice and dog clearly demonstrated that GA-AuNP was effectively distributed and retained throughout the tumor site. The CT data obtained by the present study would provide the crucial dosimetry information for strategic therapy planning using this construct. Both mice and dog did not show any clinical changes, thereby confirming that GA-AuNP did not induce toxicity and can be explored for future clinical applications.